Fcf Advisors LLC Vertex Pharmaceuticals Inc Transaction History

Fcf Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 04, 2024	BUY	$343.0 - $410.68 $747,054 - $894,461	2,178 Added 78.8%	4,942 $2.01 Million
Q3 2023 Oct 10, 2023	BUY	$338.18 - $362.46 $934,729 - $1 Million	2,764 New	2,764 $961,000
Q2 2022 Jul 20, 2022	SELL	$234.96 - $292.55 $758,450 - $944,351	-3,228 Closed	0 $0
Q1 2022 Apr 28, 2022	BUY	$221.42 - $260.97 $714,743 - $842,411	3,228 New	3,228 $842,000
Q3 2021 Oct 12, 2021	SELL	$181.39 - $202.99 $835,300 - $934,768	-4,605 Closed	0 $0
Q2 2021 Jul 30, 2021	SELL	$187.49 - $221.1 $63,934 - $75,395	-341 Reduced 6.89%	4,605 $894,000
Q1 2021 Apr 06, 2021	SELL	$207.02 - $241.31 $6,417 - $7,480	-31 Reduced 0.62%	4,946 $1.06 Million
Q4 2020 Jan 12, 2021	SELL	$207.01 - $276.09 $96,259 - $128,381	-465 Reduced 8.54%	4,977 $1.17 Million
Q3 2020 Oct 20, 2020	BUY	$255.65 - $303.1 $499,284 - $591,954	1,953 Added 55.98%	5,442 $1.47 Million
Q2 2020 Jul 10, 2020	BUY	$225.48 - $295.8 $786,699 - $1.03 Million	3,489 New	3,489 $1.02 Million

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Fcf Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Fcf Advisors LLC with notifications on news.